Shares of clinical-stage immuno-oncology company Affimed N.V. (AFMD) are up more than 20% Friday morning after the company announced positive initial data from the Phase 1 study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE), AFM13 in solid tumors.
Affimed said all four patients experienced significant disease reduction, with two complete responses and two partial responses, with an objective response rate of 100%.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com